The primary objectives of this study are to assess bronchodilator efficacy as determined by
FEV1, the effect on dyspnoea as determined by the BDI/TDI, the effect on health status as
determined by the SGRQ and the effect on COPD exacerbations.
Minimum age: 40 Years.
Maximum age: N/A.
Gender(s): Both.
1184.14.43001 Boehringer Ingelheim Investigational Site, Feldbach, Austria
1184.14.32001 Boehringer Ingelheim Investigational Site, Brussel, Belgium
1184.14.32004 Boehringer Ingelheim Investigational Site, Turnhout, Belgium
1184.14.45001 Boehringer Ingelheim Investigational Site, Hvidovre, Denmark
1184.14.45002 Boehringer Ingelheim Investigational Site, København NV, Denmark
1184.14.37202 Boehringer Ingelheim Investigational Site, Tallin, Estonia
1184.14.37201 Boehringer Ingelheim Investigational Site, Tartu, Estonia
1184.14.35802 Boehringer Ingelheim Investigational Site, Espoo, Finland
1184.14.35801 Boehringer Ingelheim Investigational Site, HUS, Finland
1184.14.3301A Boehringer Ingelheim Investigational Site, Brest, France
1184.14.3304A Boehringer Ingelheim Investigational Site, Marseille, France
1184.14.3302A Boehringer Ingelheim Investigational Site, Montpellier, France
1184.14.3303A Boehringer Ingelheim Investigational Site, Perpignan, France
1184.14.3303B Boehringer Ingelheim Investigational Site, Perpignan, France
1184.14.3303C Boehringer Ingelheim Investigational Site, Perpignan, France
1184.14.49003 Boehringer Ingelheim Investigational Site, Berlin, Germany
1184.14.49004 Boehringer Ingelheim Investigational Site, Berlin, Germany
1184.14.49006 Boehringer Ingelheim Investigational Site, Berlin, Germany
1184.14.49008 Boehringer Ingelheim Investigational Site, Berlin, Germany
1184.14.49002 Boehringer Ingelheim Investigational Site, Hamburg, Germany
1184.14.49007 Boehringer Ingelheim Investigational Site, Hamburg, Germany
1184.14.49001 Boehringer Ingelheim Investigational Site, Leipzig, Germany
1184.14.30001 Boehringer Ingelheim Investigational Site, Athens, Greece
1184.14.30004 Boehringer Ingelheim Investigational Site, Nafplio, Greece
1184.14.30006 Boehringer Ingelheim Investigational Site, Rethymno, Greece
1184.14.36002 Boehringer Ingelheim Investigational Site, Debrecen, Hungary
1184.14.36001 Boehringer Ingelheim Investigational Site, Hodmezövasarhely, Hungary
1184.14.36005 Boehringer Ingelheim Investigational Site, Komlo, Hungary
1184.14.36004 Boehringer Ingelheim Investigational Site, Miskolc, Hungary
1184.14.39001 Boehringer Ingelheim Investigational Site, Pisa, Italy
1184.14.82001 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
1184.14.82002 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
1184.14.82003 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
1184.14.37101 Boehringer Ingelheim Investigational Site, Kraslava, Latvia
1184.14.37103 Boehringer Ingelheim Investigational Site, Kuldiga, Latvia
1184.14.37102 Boehringer Ingelheim Investigational Site, Talsi, Latvia
1184.14.37003 Boehringer Ingelheim Investigational Site, Klaipeda, Lithuania
1184.14.31004 Boehringer Ingelheim Investigational Site, Eindhoven, Netherlands
1184.14.31003 Boehringer Ingelheim Investigational Site, Heerlen, Netherlands
1184.14.31002 Boehringer Ingelheim Investigational Site, Nieuwegein, Netherlands
1184.14.31001 Boehringer Ingelheim Investigational Site, Veldhoven, Netherlands
1184.14.42103 Boehringer Ingelheim Investigational Site, Bardejov, Slovakia
1184.14.46002 Boehringer Ingelheim Investigational Site, Linköping, Sweden
1184.14.46001 Boehringer Ingelheim Investigational Site, Lund, Sweden
1184.14.46003 Boehringer Ingelheim Investigational Site, Sundsvall, Sweden
1184.14.02005 Boehringer Ingelheim Investigational Site, Calgary, Alberta, Canada
1184.14.02003 Boehringer Ingelheim Investigational Site, Chilliwack, British Columbia, Canada
1184.14.02010 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
1184.14.01013 Boehringer Ingelheim Investigational Site, Boulder, Colorado, United States
1184.14.01018 Boehringer Ingelheim Investigational Site, Wheat Ridge, Colorado, United States
1184.14.01006 Boehringer Ingelheim Investigational Site, Winter Park, Florida, United States
1184.14.01003 Boehringer Ingelheim Investigational Site, Coeur D'Alene, Idaho, United States
1184.14.01015 Boehringer Ingelheim Investigational Site, South Bend, Indiana, United States
1184.14.01007 Boehringer Ingelheim Investigational Site, Lafayette, Louisiana, United States
1184.14.01005 Boehringer Ingelheim Investigational Site, Bangor, Maine, United States
1184.14.01020 Boehringer Ingelheim Investigational Site, Edina, Minnesota, United States
1184.14.01009 Boehringer Ingelheim Investigational Site, Burlington, North Carolina, United States
1184.14.01002 Boehringer Ingelheim Investigational Site, Cincinnati, Ohio, United States
1184.14.01021 Boehringer Ingelheim Investigational Site, Toledo, Ohio, United States
1184.14.02001 Boehringer Ingelheim Investigational Site, Niagara Falls, Ontario, Canada
1184.14.02002 Boehringer Ingelheim Investigational Site, La Malbaie, Quebec, Canada
1184.14.02008 Boehringer Ingelheim Investigational Site, Ste-Foy, Quebec, Canada
1184.14.01012 Boehringer Ingelheim Investigational Site, East Providence, Rhode Island, United States
1184.14.02007 Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada
1184.14.01017 Boehringer Ingelheim Investigational Site, Greenville, South Carolina, United States
1184.14.01008 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States
1184.14.01014 Boehringer Ingelheim Investigational Site, Houston, Texas, United States
1184.14.01022 Boehringer Ingelheim Investigational Site, Killeen, Texas, United States
1184.14.01001 Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States
1184.14.01010 Boehringer Ingelheim Investigational Site, Temple, Texas, United States
1184.14.01011 Boehringer Ingelheim Investigational Site, Richmond, Virginia, United States
1184.14.01019 Boehringer Ingelheim Investigational Site, Richmond, Virginia, United States